Showing 3631-3640 of 8824 results for "".
- FDA Greenlights First Treatment for Chronic Hand Eczema in Adultshttps://practicaldermatology.com/news/fda-approves-first-treatment-for-chronic-hand-eczema-in-adults/2475816/The US Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream, making it the first and only treatment approved for adults with moderate-to-severe chronic hand eczema (CHE) who are unresponsive to topical corticosteroids or for those unsuitabl
- Analysis: Arnica’s Popularity on Social Not Supported by Data for Post-Procedure Recoveryhttps://practicaldermatology.com/news/analysis-arnicas-popularity-on-social-media-outpaces-scientific-support-for-post-procedure-recovery/2475830/Social media users and health care professionals frequently endorse Arnica montana for reducing bruising and swelling following aesthetic injectables, but a recent analysis shows scientific support for its use may be lacking.
- Multimodal "Toolkit" Enhances AI Detection of Skin Lesions: Researchershttps://practicaldermatology.com/news/multimodal-dataset-enhances-ai-detection-of-skin-lesions/2475786/A new open-access dataset, MILK10k, provides over 10,000 multimodal images to improve machine learning performance in the diagnosis of both pigmented and non-pigmented skin cancers and simulators. According to researchers publ
- ADmirable Trial: Lebrikizumab Shows Efficacy in AD Among Skin of Color Populationshttps://practicaldermatology.com/news/admirable-lebrikizumab-shows-efficacy-in-ad-among-skin-of-color-populations/2475811/Lebrikizumab significantly improved atopic dermatitis (AD) outcomes in patients with skin of color in the ADmirable phase 3b trial. The ADmirable study, and open-label, 24-week trial evaluating lebrikizumab in patients with F
- Study: Frequent AD Flares Forecast Worse Outcomes in Following Yearhttps://practicaldermatology.com/news/study-frequent-ad-flares-forecast-worse-outcomes-in-following-year/2475765/Frequent flares of atopic dermatitis (AD) are predictive of worse disease severity and reduced quality of life, according to findings from a large cohort study. Researchers for the study examined data from the Danish Skin Coho
- Analysis: New Biologics Account for 70% of Increased Medicare Dermatology Drug Spendinghttps://practicaldermatology.com/news/analysis-new-biologics-account-for-70-of-increased-medicare-dermatology-drug-spending/2475722/Spending on dermatology-related drugs under Medicare Part D nearly quadrupled between 2013 and 2022, with specialty medications (including biologics) responsible for the vast majority of that increase, according to a new study.
- Long-Term Ixekizumab Use Not Linked to Increased Cancer Risk: Analysishttps://practicaldermatology.com/news/long-term-ixekizumab-use-not-linked-to-increased-cancer-risk/2475704/Long-term treatment with ixekizumab (IXE) for psoriasis, psoriatic arthritis, and axial spondyloarthritis was not associated with increased risk of malignant neoplasms, according to a new analysis of pooled data from 25 randomized clinical trials.
- LEQSELVI™ Launches in U.S. as Oral Treatment for Severe Alopecia Areatahttps://practicaldermatology.com/news/leqselvitm-launches-in-us-as-oral-treatment-for-severe-alopecia-areata/2475680/Sun Pharmaceutical Industries Ltd. announced the U.S. commercial availability of LEQSELVI™ (deuruxolitinib), an oral Janus kinase (JAK) inhibitor indicated for the treatment of adults with severe alopecia areata, according to a press release from the manufacturer.
- Upcoming Skin Cancer Champions Webinar Addresses Impact of AIhttps://practicaldermatology.com/news/Upcoming-Skin-Cancer-Champions-Webinar-Addresses-Impact-AI/2475627/Veronica Rotemberg, MD, PhD, will host a free webinar on the future of non-melanoma skin cancer care August 5 at 1:00 PM ET, Skin Cancer Champions announced. Dr. Rotemberg, Director of Dermatology Imaging Informatics for Memorial Sloan Kettering Cancer Center, will present “The Future of S
- Positive Early Results in Tralokinumab Trial for AD on Handshttps://practicaldermatology.com/news/Positive-Early-Results-Tralokinumab-Trial-AD-Hands/2475575/A trial evaluating tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD) on the hands, who are candidates for systemic therapy, met the primary endpoint and all secondary endpoints with a statistically significant improvement in AD on the hands after 16 weeks of